Alterity Therapeutics Ltd (ASX: ATH) Share Price and News
Price
$0.0105
Movement
0.0005 (-4.55%)
as at 13 Jun 1:11pm (20 mins delayed)
52 Week Range
$0.002 - $0.019
1 Year Return
+110.0%
Alterity Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$100.40 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
8.88 billion
Earnings per share
-0.004
Dividend per share
N/A
Year To Date Return
50.00%
Earnings Yield
N/A
Franking
-
Share Price
$0.0105
Day Change
0.0005 (-4.55%)
52 Week Range
$0.002 - $0.019
Yesterday's Close
$0.011
Today's Open
$0.01
Days Range
$0.01 - $0.011
Volume
4,319,623
Avg. Volume (1 month)
10,219,964
Turnover
$45,308
as at 13 Jun 1:11pm
Alterity Therapeutics Ltd (ASX: ATH)
Latest News
Healthcare Shares
Why the Alterity (ASX:ATH) share price is skyrocketing 42% today
Share Market News
Here's why the Alterity Therapeutics (ASX:ATH) share price blasted 20% higher today
Share Market News
Why Alterity Therapeutics (ASX:ATH) share price has surged up 27% today
Share Market News
Alterity (ASX:ATH) share price lower on completed placement
Investing
Why Alterity Therapeutics' share price has rocketed 96% in 2 days
Share Market News
Alterity Therapeutics share price rockets 70% on new data
Share Market News
Why Etherstack and these shares were the most traded on the ASX last week
ATH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 23rd May 2025 2025-05-23T08:20:03 | Change in substantial holding | YesNo | 8:20am | 6 | 471k |
| 12th May 2025 2025-05-12T09:54:40 | Alterity Prominently Featured at International MSA Congress | YesNo | 9:54am | 6 | 254k |
| 12th May 2025 2025-05-12T08:16:19 | Change in substantial holding | YesNo | 8:16am | 6 | 454k |
| 7th May 2025 2025-05-07T13:00:24 | Alterity Phase 2 Data to be Featured at MSA Congress | YesNo | 1:00pm | 5 | 213k |
| 5th May 2025 2025-05-05T08:53:10 | Alterity Granted U.S. FDA Fast Track Designation for ATH434 | YesNo | 8:53am | 5 | 239k |
| 30th Apr 2025 2025-04-30T09:30:38 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 9:30am | 10 | 365k |
| 29th Apr 2025 2025-04-29T13:08:28 | Change of Director's Interest Notice x 3 | YesNo | 1:08pm | 9 | 21k |
| 28th Apr 2025 2025-04-28T10:18:55 | Alterity Phase 2 Presentation at MSA Symposium 2025 | YesNo | 10:18am | 24 | 1.2M |
| 22nd Apr 2025 2025-04-22T10:31:10 | New Options - Top 20 Holders and Range of Units | YesNo | 10:31am | 3 | 85k |
| 22nd Apr 2025 2025-04-22T09:55:24 | Application for quotation of securities - ATH | YesNo | 9:55am | 7 | 18k |
About Alterity Therapeutics Ltd
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
ATH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 12 Jun 2025 | $0.01 | $0.00 | 0.00% | 16,015,754 | $0.01 | $0.01 | $0.01 |
| 11 Jun 2025 | $0.01 | $0.00 | 0.00% | 17,304,685 | $0.01 | $0.01 | $0.01 |
| 10 Jun 2025 | $0.01 | $0.00 | 0.00% | 9,391,039 | $0.01 | $0.01 | $0.01 |
| 06 Jun 2025 | $0.01 | $0.00 | 0.00% | 9,527,872 | $0.01 | $0.01 | $0.01 |
| 05 Jun 2025 | $0.01 | $0.00 | 0.00% | 12,061,808 | $0.01 | $0.01 | $0.01 |
| 04 Jun 2025 | $0.01 | $0.00 | 0.00% | 1,986,353 | $0.01 | $0.01 | $0.01 |
| 03 Jun 2025 | $0.01 | $0.00 | 0.00% | 1,259,994 | $0.01 | $0.01 | $0.01 |
| 02 Jun 2025 | $0.01 | $0.00 | 0.00% | 19,092,281 | $0.01 | $0.01 | $0.01 |
| 30 May 2025 | $0.01 | $0.00 | 0.00% | 8,219,766 | $0.01 | $0.01 | $0.01 |
| 29 May 2025 | $0.01 | $0.00 | 0.00% | 23,418,306 | $0.01 | $0.01 | $0.01 |
| 28 May 2025 | $0.01 | $0.00 | 0.00% | 2,971,652 | $0.01 | $0.01 | $0.01 |
| 27 May 2025 | $0.01 | $0.00 | 0.00% | 4,448,839 | $0.01 | $0.01 | $0.01 |
| 26 May 2025 | $0.01 | $0.00 | 0.00% | 4,350,448 | $0.01 | $0.01 | $0.01 |
| 23 May 2025 | $0.01 | $0.00 | 0.00% | 6,218,189 | $0.01 | $0.01 | $0.01 |
| 22 May 2025 | $0.01 | $0.00 | 0.00% | 9,317,104 | $0.01 | $0.01 | $0.01 |
| 21 May 2025 | $0.01 | $0.00 | 0.00% | 10,276,054 | $0.01 | $0.01 | $0.01 |
| 20 May 2025 | $0.01 | $0.00 | 0.00% | 8,004,949 | $0.01 | $0.01 | $0.01 |
| 19 May 2025 | $0.01 | $0.00 | 0.00% | 8,783,460 | $0.01 | $0.01 | $0.01 |
| 16 May 2025 | $0.01 | $0.00 | 0.00% | 2,566,776 | $0.01 | $0.01 | $0.01 |
| 15 May 2025 | $0.01 | $0.00 | 0.00% | 35,608,339 | $0.01 | $0.01 | $0.01 |
| 14 May 2025 | $0.01 | $0.00 | 0.00% | 492,369 | $0.01 | $0.01 | $0.01 |
| 13 May 2025 | $0.01 | $0.00 | 0.00% | 13,523,180 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Apr 2025 | Brian Meltzer | Issued | 757,576 | $6,060 |
Issue of options.
|
| 24 Apr 2025 | Peter Marks | Issued | 606,061 | $4,848 |
Issue of options.
|
| 24 Apr 2025 | Lawrence Gozlan | Issued | 1,515,152 | $12,121 |
Issue of options.
|
| 07 Apr 2025 | Lawrence Gozlan | Buy | 4,545,455 | $50,000 |
Placement.
|
| 07 Apr 2025 | Brian Meltzer | Buy | 2,272,727 | $25,000 |
Placement.
|
| 07 Apr 2025 | Peter Marks | Buy | 1,818,182 | $20,000 |
Placement. As per announcement on 09/04/2025.
|
| 30 Dec 2024 | Lawrence Gozlan | Issued | 50,000,000 | $400,000 |
Employee Share Ownership Plan.
|
| 30 Dec 2024 | Peter Marks | Issued | 30,000,000 | $240,000 |
Employee Share Ownership Plan.
|
| 30 Dec 2024 | Geoffrey Kempler | Issued | 60,000,000 | $480,000 |
Employee Share Ownership Plan.
|
| 30 Dec 2024 | Brian Meltzer | Issued | 30,000,000 | $240,000 |
Employee Share Ownership Plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Geoffrey Paul Kempler | Non-Executive ChairmanNon-Executive Director | Jun 2005 |
Mr Kempler has experience in investment and business development. He served as a Chairman and Non-Executive Director of Opthea Limited, from November 2015 until October 2020, is immediate past Chairman of Ausbiotech, Australia's biotechnology organization, and is a member of the Industry Advisory Board at the Turner Institute of Brain and Mental Health at Monash University, and Chair of Hexima Ltd.
|
| Mr Brian Derek Meltzer | Non-Executive Director | Dec 1999 |
Mr Meltzer has spent 25 years in investment banking. His expertise includes major property transactions, corporate advisory, corporate finance, management buyouts, venture capital and large-scale syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health and wellness, aged care, software, entertainment and finance sectors, including Director of a federal government licensed Innovation Investment Fund. In 2015 he acquired a corporate health division of an American multinational then grew it five-fold before selling it in 2021 to the subsidiary of a Canadian multinational.
|
| Mr Peter Ashley Marks | Non-Executive Director | Jul 2005 |
Mr Marks has over 35 years of experience in corporate advisory and investment banking. Over the course of his long career, he has specialised in capital raisings, IPOs, cross border, M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the United States and Israel. He has been involved in a broad range of transactions with a special focus in the life sciences, biotechnology, medical technology and high-tech segments.
|
| Mr Lawrence Bernard Gozlan | Non-Executive Director | Aug 2011 |
Mr Gozlan is a biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide high level expertise and to manage investments for high-net-worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry. Prior to this, Mr. Gozlan was responsible for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (The Queensland Investment Corporation), an investment fund with over A$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd and gained senior corporate finance experience advising life sciences companies at Deloitte.
|
| Ms Abby Macnish Niven | Company Secretary | Nov 2024 |
-
|
| Dr David Stamler | Chief Executive Officer | Jan 2021 |
-
|
| David Stamler | Chief Executive Officer |
-
|
|
| Abby Macnish Niven | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 2,181,650,785 | 41.01% |
| Citicorp Nominees Pty Limited | 166,549,148 | 3.13% |
| Buttonwood Nominees Pty Ltd | 103,382,234 | 1.94% |
| Kyriaco Barber Pty Ltd | 65,000,000 | 1.22% |
| MST Financial Services Pty Ltd | 52,517,122 | 0.99% |
| Andrew Mark Wilmot Seton | 44,203,475 | 0.83% |
| One Managed Investment Funds Limited <Ti Growth A/C> | 42,857,143 | 0.81% |
| Mrs Amanda Kay Lang | 40,026,452 | 0.75% |
| Capuano Nominees Pty Ltd <The Hartman Investment A/C> | 40,000,000 | 0.75% |
| Jagen Pty Ltd | 38,556,497 | 0.72% |
| Mr Buu Lan Au | 37,211,096 | 0.70% |
| M F Cunningham Pty Ltd <Cunningham S/F A/C> | 35,571,429 | 0.67% |
| Satur Investments Pty Ltd <Satur Super Fund A/C> | 32,271,429 | 0.61% |
| Spiceme Capital Pty Ltd | 30,000,000 | 0.56% |
| Mr Jeffrey Ernst Keller + Mr Kim Aaron Muller <Kim Muller Super Fund A/C> | 29,354,184 | 0.55% |
| Mr Craig Graeme Chapman <Nampac Discretionary A/C> | 28,571,429 | 0.54% |
| Ms Elif Ceren Gunes | 28,571,429 | 0.54% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 27,310,604 | 0.51% |
| BNP Paribas Noms Pty Ltd | 26,886,761 | 0.51% |
| Mr Scott Anthony Nicholls | 26,000,000 | 0.49% |